Effect of statin for CKD with hyperlipidemia

Phase 4

• Conditions: chronic kidney disease

• Registration Number: JPRN-UMIN000006600
• Lead Sponsor: Dept. of Nephrology, Univ. of Tsukuka

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-11-01
• Study Completion: 2014-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patient taking HMG-CoA reductase inhibitors 2. Patient taking cyclosporin. 3. Patient taking glucocorticoid 4. eGFR<15, or liver dysfunction 5. Patient with nephrotic syndrome 6. Patients with malignacy 7. Pregnant or nursing woman 8. Familial hypercholesteremia 9. LDL-C>200mg/dL 10. Patient who donot give written informed consent 11.Patient with diagnosis inadequacy for doctor in attendance

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percent change of estimated GFR

Secondary Outcome Measures

Name	Time	Method
1. Changes of plasma and urine parameters related to renal function and dyslipidemia (T-Chol, TG, HDL-C, LDL-C, UN, Cr, TP, Alb, hs-CRP, cystatin C, HbA1C, AST, ALT, gamma-GTP, CK, urinary protein, urine protein creatinine ratio) 2. Adverse reactions